Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9
|
作者：
Nie, Run-Cong [1 ]
Duan, Shu-Qiang YuanJin-Ling [1 ,3 ]
Liang, Yao [1 ]
Chen, Xiao-Jiang [1 ]
Chen, Yong-Ming [1 ]
Luo, Tian-Qi [1 ]
Chen, Guo-Ming [1 ]
Wang, Yun [2 ]
Li, Yuan-Fang [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 18期
关键词：
efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.2217/imt-2020-0007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
引用
收藏
页码：1313 / 1324
页数：12
相关论文
共 50 条
  • [41] The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
    Huang, Guanghong
    Sun, Xin
    Liu, Dapeng
    Zhang, Yunfeng
    Zhang, Boxiang
    Xiao, Guodong
    Li, Xiang
    Gao, Xiao
    Hu, Chenhao
    Wang, Meng
    Ren, Hong
    Qin, Sida
    ONCOTARGET, 2018, 9 (03) : 4239 - 4248
  • [42] Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
    Yusof, Mohd Nazzary
    Chew, Kah Teik
    Hafizz, Abdul Muzhill Hannaan Abdul
    Abd Azman, Siti Hajar
    Ab Razak, Wira Sofran
    Hamizan, Muhammad Rafi'uddin
    Kampan, Nirmala Chandralega
    Shafiee, Mohamad Nasir
    CANCERS, 2023, 15 (16)
  • [43] Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
    Yang, Yuanyuan
    Wang, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
    Xiang, Ze
    Li, Jiayuan
    Zhang, Zhengyu
    Cen, Chao
    Chen, Wei
    Jiang, Bin
    Meng, Yiling
    Wang, Ying
    Berglund, Bjoern
    Zhai, Guanghua
    Wu, Jian
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis
    Zhou, Xueyin
    Cao, Jiasheng
    Topatana, Win
    Xie, Tianao
    Chen, Tianen
    Hu, Jiahao
    Li, Shijie
    Juengpanic, Sarun
    Lu, Ziyi
    Zhang, Bin
    Wang, Kaitai
    Feng, Xu
    Shen, Jiliang
    Chen, Mingyu
    IMMUNOTHERAPY, 2023, 15 (05) : 353 - 365
  • [46] The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
    Lihu Gu
    Parikshit Asutosh Khadaroo
    Hui Su
    Liya Kong
    Liangliang Chen
    Xianfa Wang
    Xinlong Li
    Hepan Zhu
    Xin Zhong
    Junhai Pan
    Manman Chen
    BMC Cancer, 19
  • [47] The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
    Gu, Lihu
    Khadaroo, Parikshit Asutosh
    Su, Hui
    Kong, Liya
    Chen, Liangliang
    Wang, Xianfa
    Li, Xinlong
    Zhu, Hepan
    Zhong, Xin
    Pan, Junhai
    Chen, Manman
    BMC CANCER, 2019, 19 (1)
  • [48] COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES
    Aggarwal, S.
    Topaloglu, O.
    Kumar, S.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [49] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Yuwei Liu
    Jiahui Pan
    Fangbo Gao
    Wentao Xu
    Hongyu Li
    Xingshun Qi
    Advances in Therapy, 2023, 40 : 521 - 549
  • [50] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis (vol 73, 155, 2024)
    Chen, Yueying
    Han, Hedong
    Cheng, Jing
    Cheng, Qinpei
    Zhu, Suhua
    Zhan, Ping
    Liu, Hongbing
    Song, Yong
    Lv, Tangfeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
12345